Corentec Co., Ltd. announced that it expects to receive KRW 3.5000021 billion in funding from Union Pharmacy Co. Ltd., Seoul Pharmacy Do Ltd, and other investor
July 25, 2019
Share
Corentec Co., Ltd. (KOSDAQ:A104540) announced that it will issue 621,670 redeemable convertible preferred stock of face value of KRW 500 at issue price of KRW 5,630 per share for gross proceeds of KRW 3,500,002,100 on July 25, 2019. The transaction includes participation from Union Pharmacy Co. Ltd. for 177,620 shares, Seoul Pharmacy Do Ltd for 177,620 shares, and UMC Holdings Co., Ltd. for 266,430 shares. The shares will be redeemable from August 19, 2024 to August 19, 2034. The transaction is expected to complete on August 5, 2019. The transaction has been approved by the board of directors of the company. The shares issued in the transaction is subject to a lock up period of one year
Corentec Co., Ltd. is a Korea-based company engaged in the development, manufacture and sale of orthopedic implants. The Companyâs products consist of hip products, including primary systems, hemi-arthroplasty systems and revision systems, such as cementless femoral stems, cemented femoral stems, cups for acetabular systems, bearing systems and others; knee products, including primary knee system fixed type, primary knee system mobile type, revision knee systems and augments systems, and spine products, including pedicle screws and peek cages. The Company mainly provides its hip products under the brand name of BENCOX, knee products under the brand name of LOSPA and spine products under the brand name of LOSPA IS. The Company distributes its products within domestic market and to overseas markets.
Corentec Co., Ltd. announced that it expects to receive KRW 3.5000021 billion in funding from Union Pharmacy Co. Ltd., Seoul Pharmacy Do Ltd, and other investor
CORENTEC CO., LTD. 